Skip to main content
. 2022 Jan 27;208(3):323–331. doi: 10.1093/cei/uxac009

Figure 3.

Figure 3.

Comparison of antibody titres to RBD of the SARS-CoV-2 using the HAT assay in those with varying severity of infection and in vaccines. Antibody titres were measured in individuals with mild illness to the WT, B.1.1.7 (α), B.1.351 (β), and B.1.617.2 (λ) at 4 weeks (n = 15) and 12 weeks (n = 14) since the onset of illness (A), in those with moderate/severe illness at 4 weeks (n = 15) and 12 weeks (n = 6) since onset of illness (B) and in those who received one dose of AZD1222 vaccine at 4 weeks (n = 20) and 12 weeks (n = 20) following the vaccine (C). The difference between antibody titres to WT, B.1.1.7 (α), B.1.351 (β), and B.1.617.2 (λ) was determined using the Wilcoxon paired t-test (two-tailed). The lines indicate the median and the interquartile range.